Interestingly peroxisome proliferator-activated receptor γ (PPARγ) agonist are insulin sensitizers and widely used in the treatment of type 2 diabetes and cardiac hypertrophy has been reported in few preclinical studies using such agonists [66]. This evidence concerns the gene PPARG and type 2 diabetes mellitus.